Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Source: NASDAQ.COM
Biorestorative Therapies Earnings Report: Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.3 per share, better than the expected loss of $0.41, and achieved revenues of $0.3 million, surpassing estimates by 51.50%. The company has shown mixed performance in earnings estimate revisions, currently holding a Zacks Rank #3 (Hold).
Industry Outlook and Comparisons: The Medical - Biomedical and Genetics industry is ranked in the bottom 43% of Zacks industries, impacting stock performance expectations. Ayr Wellness Inc. (AYRWF), another company in the sector, is anticipated to report a loss with declining revenue projections for the upcoming quarter.
Analyst Views on BRTX
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.155
Low
8.00
Averages
8.00
High
8.00
Current: 1.155
Low
8.00
Averages
8.00
High
8.00
No data
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
